Cited by 728Pluripotent Stem Cells ResearchCRISPR and Genetic EngineeringParkinson's Disease Mechanisms and Treatments

Generation of Isogenic Pluripotent Stem Cells Differing Exclusively at Two Early Onset Parkinson Point Mutations

Open access
Soldner, Frank, Laganière, Josée, Cheng, Albert W., Hockemeyer, Dirk, Gao, Qing, Alagappan, Raaji, Khurana, Vikram, Golbe, Lawrence I. +12 more·2011·Cell

Abstract

Patient-specific induced pluripotent stem cells (iPSCs) derived from somatic cells provide a unique tool for the study of human disease, as well as a promising source for cell replacement therapies. One crucial limitation has been the inability to perform experiments under genetically defined conditions. This is particularly relevant for late age onset disorders in which in vitro phenotypes are predicted to be subtle and susceptible to significant effects of genetic background variations. By combining zinc finger nuclease (ZFN)-mediated genome editing and iPSC technology, we provide a generally applicable solution to this problem, generating sets of isogenic disease and control human pluripotent stem cells that differ exclusively at either of two susceptibility variants for Parkinson's disease by modifying the underlying point mutations in the α-synuclein gene. The robust capability to genetically correct disease-causing point mutations in patient-derived hiPSCs represents significant progress for basic biomedical research and an advance toward hiPSC-based cell replacement therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cell.2011.06.019

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • CRISPR-induced DNA breaks are especially toxic to iPSCs, lowering survival and potentially confounding observed phenotypes.

    “However, CRISPR-induced DNA breaks are particularly toxic to iPSCs111, reducing cell survival and potentially confounding the observed phenotypes.”

    From CRISPR-based functional genomics for neurological disease (2020) · cites this paper as [111]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Soldner, F., Laganière, J., Cheng, A. W., Hockemeyer, D., Gao, Q., Alagappan, R., Khurana, V., Golbe, L. I., Myers, R. H., Lindquist, S., Zhang, L., Guschin, D., Fong, L. K., Vu, B. J., Meng, X., Urnov, F. D., Rebar, E. J., Gregory, P. D., Zhang, H. S., & Jaenisch, R.
Affiliations
  • Whitehead Institute for Biomedical Research (US)
  • Sangamo BioSciences (United States) (US)
  • Brigham and Women's Hospital (US)
  • Rutgers, The State University of New Jersey (US)
  • Boston University (US)
Corresponding author
Jaenisch, Rudolf
Venue
Cell
Publisher
Elsevier BV
Published
2011-07
Volume
146
Issue
2
Pages
318-331
ISSN
0092-8674 (ISSN-L)
OpenAlex
W2154679217
Cited by
728
References
58
Citations by year
2026: 7 · 2025: 16 · 2024: 21 · 2023: 24 · 2022: 21 · 2021: 36 · 2020: 29 · 2019: 36 · 2018: 52 · 2017: 48 · 2016: 69 · 2015: 83 · 2014: 92 · 2013: 77 · 2012: 86
FWCI
36.97
Type
journal article
Language
en
Update notices
erratum (2011-08-19)
Open access
Locations
  • Cell (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
Funders
  • Howard Hughes Medical Institute
  • Life Sciences Research Foundation
  • National Institutes of Health (2r01ca084198-10, HD 045022)
  • National Cancer Institute (R01-CA084198)
  • National Institute of Neurological Disorders and Stroke (R01NS076843)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD045022, R37HD045022)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords
Parkinson's disease, induced pluripotent stem cells, alpha-synuclein, point mutations, zinc finger nucleases, genome editing, gene correction, disease modeling, cell replacement therapy, genetic background
MeSH terms
Cell Line, Genetic Engineering, Humans, Oligonucleotides, Parkinson Disease, Mutagenesis, Point Mutation, Pluripotent Stem Cells, alpha-Synuclein, Embryonic Stem Cells, Genome-Wide Association Study

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review